Kyverna Therapeutics

KYTXNasdaq United States Health Care Biotechnology: Biological Products (No Diagnostic Substances)

Market cap

$483.930 M

$7.96 +2.71%

Close of 7 Aug 2026

Revenue

—

Not reported

Earnings

-$161.3M

Loss-making

Shares outstanding

60,439,893

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: Biological Products (No Diagnostic Substances) — ranked by market cap

All 160 →

#69ProkidneyPROK$495.4M
#70Ginkgo BioworksDNA$495.2M
#71Kyverna TherapeuticsKYTX$483.9M
#72Cabaletta BioCABA$454.9M
#73Editas MedicineEDIT$442.3M

Where these numbers come from

Share counts and financials for Kyverna Therapeutics are taken from its own SEC filings via EDGAR — public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Last updated 9 Aug 2026. Read the methodology.